JPMorgan keeps CNY 240.00 target for Mindray stock

JPMorgan maintained its Buy rating and CNY 240.00 target for Mindray stock on September 1, 2026, according to Investing.com. Against Mindray's Shenzhen price of CNY 164.94, that target stands 45.51 percent higher. Mindray stock was last at CNY 164.94 on Shenzhen on October 13, 2026 at 3:04 p.m. CST, down 0.64 percent versus the Shenzhen prior close of CNY 166.00.

Revenue rose in first-half 2026

Mindray reported revenue of RMB 17.747 billion in the first half of 2026, up 6.00 percent year over year, while net profit attributable to shareholders fell 5.37 percent to RMB 4.797 billion, according to Futunn. Adjusted net profit attributable to shareholders reached RMB 4.785 billion, down 3.32 percent in the same period.

The mix was more favorable outside China. Overseas revenue reached RMB 9.471 billion, up 13.67 percent in the first half, while emerging-business revenue rose 19.59 percent to RMB 3.110 billion, according to the same September 30, 2026 report by Futunn.

Price sits inside the yearly range

The CNY 164.94 price is 31.22 percent below the CNY 239.79 52-week high and 26.21 percent above the CNY 130.66 low, with both levels dated October 13, 2026. Trading volume was 7,401,935 shares against an average of 9,441,200, leaving the session volume 21.60 percent below its average.

Valuation and October reporting date

Mindray's market capitalization was CNY 200.0 billion and its price-to-earnings ratio was 25.41 on October 13, 2026. The next earnings report is scheduled for October 26, 2026, according to Investing.com.

Comparison with peers

Mindray: minus 0.64 percent, P/E 25.41, market capitalization CNY 200.0 billion

United Imaging (Shanghai, CNY): minus 1.09 percent, P/E 78.12, market capitalization CNY 87.6 billion

Lepu Medical (Shenzhen, CNY): minus 1.88 percent, P/E 27.44, market capitalization CNY 21.2 billion

Mindray stock and the next report

The combination of 6.00 percent first-half revenue growth and a 5.37 percent decline in reported net profit leaves the October 26 report as the next dated test for whether overseas and emerging businesses can offset pressure on margins. The stock's CNY 164.94 level remains closer to the yearly low than the high, while JPMorgan's CNY 240.00 target provides a separate valuation reference dated September 1, 2026.

Market context: Market report Shanghai Composite.

Market context: Market report Shanghai Composite.

More news and analyses on Mindray stock